GlassScriptPhysician profile
Muhammad M Amin
NPI 1902834930
$607.23
in general payments reported to CMS, 2019-2025
15 companies · $141 in 2025
The $141 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28.00 · 2020: $31.08 · 2021: $24.69 · 2022: $86.07 · 2023: $175 · 2024: $122 · 2025: $141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $437.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $437.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $105.90 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $69.65 | 2023-2024 | Gardasil 9, Capvaxive, M-M-R II |
| Baudax Bio INC. | $62.63 | 2020-2022 | |
| Mylan Specialty L.P. | $60.25 | 2023-2024 | Yupelri, Perforomist |
| Ferring Pharmaceuticals INC. | $49.41 | 2023 | Rebyota |
| Sanofi Pasteur INC. | $47.59 | 2022-2025 | |
| Daiichi Sankyo INC. | $34.79 | 2023 | Injectafer |
| Sunovion Pharmaceuticals INC. | $28.00 | 2019 | |
| Exact Sciences Corporation | $27.00 | 2025 | The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $25.78 | 2025 | Airsupra |
| Opko Pharmaceuticals, LLC | $22.20 | 2024 | Rayaldee |
| Viatris Specialty LLC | $20.08 | 2025 | Yupelri |
| Calliditas Therapeutics US INC. | $18.45 | 2023 | Tarpeyo |
| Kerecis Limited | $18.37 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Boston Scientific Corporation | $17.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Amin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.